Advertisement

Sympathetic Nervous System and Hypertension

  • H. Thoenen
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Innere Medizin book series (VDGINNERE, volume 80)

Abstract

The role of the sympathetic nervous system in the pathogenesis of essential human hypertension is not yet established [6, 7, 10, 11, 25, 36]. In spite of this the majority of drugs currently used in the treatment of human hypertension act by modifying peripheral and/or central adrenergic mechanisms [27]. Whereas the site and mode of action is relatively well understood in the peripheral sympathetic nervous system this is much less the case for centrally acting drugs.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andén, N.-E., Corrodi, H., Fuxe, K., Hökfelt, B., Hökfelt, T., Svensson, T.: Life Sci. 9, 513 (1970).PubMedCrossRefGoogle Scholar
  2. 2.
    Antonaccio, M. J., Robson, R. D., Burrell, R.: Europ. J. Pharmacol. 25, 9 (1974).CrossRefGoogle Scholar
  3. 3.
    Bolme, P., Fuxe, K.: Europ. J. Pharmacol. 13, 168 (1971).CrossRefGoogle Scholar
  4. 4.
    Brodie, B. B., Costa, E., Dlabac, A., Neff, N. H., Smookler, H. H.: J. Pharmacol. exp. Ther. 154, 493 (1966).PubMedGoogle Scholar
  5. 5.
    Chalmers, J. P., Wurtman, R. J.: Circulat. Res. 28, 480 (1971).PubMedCrossRefGoogle Scholar
  6. 6.
    de Champlain, J., Karkoff, L. R., Axelrod, J.: Circulat. Res. 20, 136 (1967).PubMedCrossRefGoogle Scholar
  7. 7.
    de Champlain, J., Mueller, R. A., Axelrod, J.: Circulat. Res. 25, 285 (1969).PubMedCrossRefGoogle Scholar
  8. 8.
    Costa, E., Neff, N. H.: In: Topics in medical chemistry 2, 65. New York: Interscience Publ. 1968.Google Scholar
  9. 9.
    Davies, R. O., Edwards, M. W.: Brain Res. 64, 451 (1973).PubMedCrossRefGoogle Scholar
  10. 10.
    Freedman, L. S., Roffman, M., Goldstein, M.: In: Frontiers in catecholamine research, p. 1109. ( Usdin, E., Snyder, S., Eds.) New York: Perga-mon Press 1973.Google Scholar
  11. 11.
    Geffen, L. B., Rush, R. A.: In: Frontiers in catecholamine research, p. 483 ( Usdin, E., Snyder, S., Eds.). New York: Pergamon Press 1973.Google Scholar
  12. 12.
    Gerold,’ M., Tschirky, H.: Arzneimittel-Forsch. 18, 1285 (1968).Google Scholar
  13. 13.
    Gordon, R., Reid, J. V. O., Sjördsma, A., Udenfriend, S.: Molec. Pharmacol. 2, 610 (1966).Google Scholar
  14. 14.
    de Groat, W. C., Lalley, P. M.: Brain Res. 64, 460 (1973).PubMedCrossRefGoogle Scholar
  15. 15.
    Haeusler, G.: In: Frontiers in catecholamine research, p. 879 ( Usdin, E., Snyder, S., Eds.). New York: Pergamon Press 1973.Google Scholar
  16. 16.
    Haeusler, G.: Naunyn-Schmiedebergs Arch. Pharmacol. 278, 231 (1973).Google Scholar
  17. 17.
    Haeusler, G., NaunynSchmiedebergs Arch. Pharmacol. R 29 (1974).Google Scholar
  18. 18.
    Heise, A., Kroneberg, G.: Europ. J. Pharmacol. 17, 315 (1972).CrossRefGoogle Scholar
  19. 19.
    Henning, M., van Zwieten, P. A.: J. Pharm. Pharmacol. 20, 407 (1968).CrossRefGoogle Scholar
  20. 20.
    Hoyer, I., van Zwieten, P. A.: J. Pharm. Pharmacol. 24, 452 (1972).PubMedCrossRefGoogle Scholar
  21. 21.
    Kale, A. K., Satoskar, R. S.: Europ. J. Pharmacol. 9, 120 (1970).CrossRefGoogle Scholar
  22. 22.
    Kobinger, W., Walland, A.: Arzneimittel-Forsch. 17, 292 (1967).Google Scholar
  23. 23.
    Kobinger, W., Walland, A.: Europ. J. Pharmacol. 2, 155 (1967).CrossRefGoogle Scholar
  24. 24.
    Kobinger, W., Walland, A.: Europ. J. Pharmacol. 19, 210 (1972).CrossRefGoogle Scholar
  25. 25.
    Louis, W. J., Krauss, K. R., Kopin, I. J., Sjördsma, A.: Circulat. Res. 27, 589 (1970).PubMedCrossRefGoogle Scholar
  26. 26.
    Nakamura, K., Gerold, M., Thoenen, H.: Naunyn-Schmiedebergs Arch. Pharmak. 268, 125 (1971).Google Scholar
  27. 27.
    Nickerson, M.: In: The pharmacological basis of therapeutics, p. 728 ( Goodman and Gilman, Eds.). London: Macmillan 1970.Google Scholar
  28. 28.
    Philippu, A., Przuntek, H., Heyd, G., Burger, A.: Europ. J. Pharmacol. 15, 200 (1971).CrossRefGoogle Scholar
  29. 29.
    Reis, D. J., Doba, N., Amer, M. S.: In: Frontiers in catecholamine research, p. 883 ( Usdin, E., Snyder, S., Eds.). New York: Pergamon Press 1973.Google Scholar
  30. 30.
    Roth, R. H., Stjbrne, L., von Euler, U. S.: Life Sci. 5, 1071 (1966).PubMedCrossRefGoogle Scholar
  31. 31.
    Sattler, R. W., von Zwieten, P. A.: Europ. J. Pharmacol. 2, 9 (1967).CrossRefGoogle Scholar
  32. 32.
    Schanberg, S. M., Stone, R. A., Kirshner, N., Gunnells, J. C., Robinson, R. R.: Science 183, 523 (1974).PubMedCrossRefGoogle Scholar
  33. 33.
    Schmitt, H., Schmitt, H.: Europ. J. Pharmacol. 9, 7 (1970).CrossRefGoogle Scholar
  34. 34.
    Schmitt, H., Schmitt, H., Fénard, S.: Europ. J. Pharmacol. 14, 98 (1971).CrossRefGoogle Scholar
  35. 35.
    Sedvall, G. C., Kopin, I. J.: Life Sci. 6, 45 (1967).PubMedCrossRefGoogle Scholar
  36. 36.
    Sjördsma, A.: In: Frontiers in catecholamine research, p. 635 ( Usdin, E., Snyder, S. Eds.). New York: Pergamon Press 1973.Google Scholar
  37. 37.
    Thierry, A. M., Javoy, F., Glowinski, J., Kety, S. S.: J. Pharmacol. exp. Ther. 163, 163 (1968).PubMedGoogle Scholar
  38. 38.
    Torchiana, M. L., Lotti, V. J., Clark, C. M., Stone, C. A.: Arch. int. Pharmacodyn. 205, 103 (1973).PubMedGoogle Scholar
  39. 39.
    Ungerstedt, U.: Acta physiol. stand. Suppl. 367, 1 (1971).Google Scholar
  40. 40.
    Watanabe, A. M., Chase, T. N., Cardon, P. V.: Clin. Pharmacol. Ther. 11, 740 (1970).Google Scholar
  41. 41.
    Yamori, Y., de Jong, W., Yamabe, H., Lovenberg, W., Sjördsma, A.: J. Pharm. Pharmacol. 24, 690 (1972).PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1974

Authors and Affiliations

  • H. Thoenen
    • 1
  1. 1.Department of PharmacologyBiocenter Univ. BaselSwitzerland

Personalised recommendations